Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 27, Issue 6, 2009, Pages 964-970

  Palomino Morales, Rogelio ^a   Gonzalez Juanatey, Carlos ^b   Vazquez Rodriguez, Tomas R ^b   Miranda Filloy, Jose A ^b   Llorca, Javier ^c   Martin, Javier ^a   Gonzalez Gay, Miguel A ^b  

^a CSIC   (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

^c UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Atherosclerosis; Cardiovascular disease; Cytokine; Gene polymorphism; IL 6; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; INFLIXIMAB; INTERLEUKIN 6; RHEUMATOID FACTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD FLOW; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; ENDOTHELIAL DYSFUNCTION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; VASODILATATION;

ADULT; AGED; ALLELES; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CHI-SQUARE DISTRIBUTION; ENDOTHELIUM; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SEVERITY OF ILLNESS INDEX;

EID: 76649083245     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. FELDMANN M, BRENNAN FM, MAINI RN: Rheumatoid arthritis. Cell 1996; 85: 307-10.
2. NISHIMOTO N, KISHIMOTO T: Interleukin 6: From bench to bedside. Nat Clin Pract Rheumatol 2006; 2: 619-26.
3. GONZALEZ-JUANATEY C, LLORCA J, MIRANDA-FILLOY JA et al.: Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57: 287-93.
4. GOODSON NJ, SYMMONS DP, SCOTT DG, BUNN D, LUNT M, SILMAN AJ: Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005; 52:2293-9.
5. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J: Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8-17.
6. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, PIÑEIRO A, GARCIA-PORRUA C, TESTA A, LLORCA J: High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1219-23.
7. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, LOPEZ-DIAZ MJ et al.: HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 125-32.
8. FISHMAN D, FAULDS G, JEFFERY R et al.: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-76.
9. OROZCO G, RUEDA B, MARTIN J: Genetic basis of rheumatoid arthritis. Biomed Pharmacother 2006; 60: 656-62.
10. DESSEIN PH, JOFFE BI, VELLER MG et al.: Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005; 32: 435-42.
11. GREGERSEN PK, SILVER J, WINCHESTER RJ: The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum1987; 30: 1205-13.
12. GONZALEZ-GAY MA, GARCIA-PORRUA C, HAJEER AH: Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum 2002; 31: 355-60.
13. GONZALEZ-JUANATEY C, TESTA A, GARCIA-CASTELO A et al.: HLA-DRB1 status influences endothelial dysfunction in long-term treated patients with rheumatoid arthritis. Am J Med 2003; 114: 647-52.
14. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J: Inflammation and endothelial dysfunction in rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 115-7.
15. GONZALEZ-GAY MA, LLORCA J, PALOMINO-MORALES R, GOMEZ-ACEBO I, GONZALEZ-JUANATEY C, MARTIN J: Influence of nitric oxide synthase gene polymorphisms on the risk of cardiovascular events in rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 116-9.
16. PASCUAL M, NIETO A, MATARÁN L, BALSA A, PASCUAL-SALCEDO D, MARTÍN J: IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 2000; 1: 338-40.
17. DAHLQVIST SR, ARLESTIG L, SIKSTRÖM C, LINGHULT S: Tumor necrosis factor receptor type II (exon 6) and interleukin-6 (-174) gene polymorphisms are not associated with family history but tumor necrosis factor receptor type II is associated with hypertension in patients with rheumatoid arthritis from northern Sweden. Arthritis Rheum 2002; 46: 3096-8.
18. MARTINEZ A, PASCUAL M, PASCUAL-SALCEDO D, BALSA A, MARTIN J, DE LA CONCHA EG: Genetic polymorphisms in Spanish rheumatoid arthritis patients: an association and linkage study. Genes Immun 2003; 4: 117-21.
19. PAWLIK A, WRZESNIEWSKA J, FLORCZAK M, GAWRONSKA-SZKLARZ B, HERCZYNSKA M: IL-6 promoter polymorphism in patients with rheumatoid arthritis. Scand J Rheumatol 2005; 34: 109-13.
20. MARINOU I, HEALY J, MEWAR D et al.: Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. Arthritis Rheum 2007; 56: 2549-56.
21. BRUNNER H, COCKCROFT JR, DEANFIELD J et al.; AND THE WORKING GROUP ON ENDOTHELINS AND ENDOTHELIAL FACTORS OF THE EUROPEAN SOCIETY OF HYPERTENSION: Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. J Hypertens 2005; 23: 233-46.
22. DEANFIELD J, DONALD A, FERRI C et al.; AND THE WORKING GROUP ON ENDOTHELIN AND ENDOTHELIAL FACTORS OF THE EUROPEAN SOCIETY OF HYPERTENSION: Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds. J Hypertens 2005; 23: 7-17.
23. NADAR S, BLANN AD, LIP GY: Endothelial dysfunction: methods of assessment and application to hypertension [review]. Curr Pharm Des 2004; 10: 3591-605.
24. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
25. GONZALEZ-GAY MA, GARCIA-PORRUA C, GUERRERO J, RODRIGUEZ-LEDO P, LLORCA J: The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003; 49: 388-93.
26. VITA JA, KEANEY JF JR: Endothelial function: a barometer for cardiovascular risk? Circulation 2002; 106: 640-2.
27. GONZALEZ-JUANATEY C, TESTA A, GARCIA-CASTELO A, GARCIA-PORRUA C, LLORCA J, GONZALEZ-GAY MA: Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004; 51: 447-50.
28. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR, MARTIN J, LLORCA J: Endothelial dysfunction, carotid intima-media-thickness and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 2008; 38: 67-70.
29. DE BACKER G, AMBROSIONI E, BORCH-JOHNSEN K et al.: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10.
30. HERNÁNDEZ-RODRÍGUEZ J, SEGARRA M, VILARDELL C et al.: Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003; 107: 2428-34.
31. RAMOS-CASALS M, GARCÍA-CARRASCO M, CERVERA R et al.: Th1/Th2 cytokine imbalance in patients with Sjögren syndrome secondary to hepatitis C virus infection. Semin Arthritis Rheum 2002; 32: 56-63.
32. DESSEIN PH, JOFFE BI, SINGH S: Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R634-43.
33. DESSEIN PH, JOFFE BI: Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 161-7.
34. SMOLEN JS, BEAULIEU A, RUBBERT-ROTH A et al.: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doubleblind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.
35. GONZALEZ-GAY MA, HAJEER AH, DABABNEH A et al.: IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2002; 20: 179-84.
36. SALVARANI C, CASALI B, FARNETTI E et al.: Interleukin-6 promoter polymorphism at position-174 in giant cell arteritis. J Rheumatol 2005; 32: 2173-7.
37. AMOLI MM, MARTIN J, MIRANDA-FILLOY JA, GARCIA-PORRUA C, OLLIER WE, GONZALEZ-GAY MA: Lack of association between interleukin-6 promoter polymorphism at position -174 and Henoch-Schönlein purpura. Clin Exp Rheumatol 2007; 25 (Suppl. 44): S6-9.
38. LIBRA M, SIGNORELLI SS, BEVELACQUA Y et al.: Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 2006; 59: 211-5.
39. MYŚLIWSKA J, WIECKIEWICZ J, HAK L et al.: Interleukin 6 polymorphism corresponds to the number of severely stenosed coronary arteries. Eur Cytokine Netw 2006; 17: 181-8.
40. FLEX A, GAETANI E, PAPALEO P et al.: Pro-inflammatory genetic profiles in subjects with history of ischemic stroke. Stroke 2004; 35: 2270-5.
41. BALDING J, LIVINGSTONE WJ, PITTOCK SJ et al.: The IL-6 G-174C polymorphism may be associated with ischaemic stroke in patients without a history of hypertension. Ir J Med Sci 2004; 173: 200-3.
42. TSO AR, MERINO JG, WARACH S: Interleukin-6 174G/C polymorphism and ischemic stroke: a systematic review. Stroke 2007; 38: 3070-5.
43. BERG KK, MADSEN HO, GARRED P, WISETH R, GUNNES S, VIDEM V: The additive contribution from inflammatory genetic markers on the severity of cardiovascular disease. Scand J Immunol 2009; 69: 36-42.
44. PANOULAS VF, STAVROPOULOS-KALINOGLOU A, METSIOS GS et al.: Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: The role of obesity and smoking. Atherosclerosis 2008; 204: 178-83.